{"id":"combination-of-neostigmine-and-glycopyrrolate","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Increased salivation (despite glycopyrrolate)"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Dry mouth (from glycopyrrolate)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, enhancing neuromuscular transmission and parasympathetic activity. Glycopyrrolate is an anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing unwanted parasympathomimetic effects such as excessive salivation, bronchospasm, and bradycardia that would otherwise result from neostigmine monotherapy. This combination allows therapeutic cholinergic effects while mitigating adverse effects.","oneSentence":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract parasympathomimetic side effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:44.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of neuromuscular blockade in anesthesia"},{"name":"Myasthenia gravis (neostigmine component)"}]},"trialDetails":[{"nctId":"NCT04027972","phase":"EARLY_PHASE1","title":"Pharmacokinetics of Neostigmine and Glycopyrrolate","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2020-03-09","conditions":"Spinal Cord Injuries, Constipation, Fecal Incontinence","enrollment":13},{"nctId":"NCT06351852","phase":"EARLY_PHASE1","title":"Transdermal Administration by a Novel Wireless Iontophoresis Device","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2022-03-22","conditions":"Spinal Cord Injuries, Constipation, Fecal Incontinence","enrollment":2},{"nctId":"NCT03909165","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-23","conditions":"Neuromuscular Blockade","enrollment":145},{"nctId":"NCT06351995","phase":"PHASE3","title":"Neostigmine and Glycopyrrolate by Iontophoresis","status":"ACTIVE_NOT_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2020-11-06","conditions":"Spinal Cord Injuries, Constipation, Fecal Incontinence","enrollment":6},{"nctId":"NCT04671030","phase":"PHASE1","title":"Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2018-01-15","conditions":"Spinal Cord Injuries, Constipation, Neurogenic Bowel","enrollment":6},{"nctId":"NCT03351608","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Neuromuscular Blockade","enrollment":288},{"nctId":"NCT00473694","phase":"PHASE3","title":"Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-11-28","conditions":"Anesthesia, General","enrollment":182},{"nctId":"NCT02375217","phase":"PHASE4","title":"\"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy\"","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2014-10","conditions":"Anesthesia Recovery","enrollment":56},{"nctId":"NCT01511627","phase":"NA","title":"Randomized Controlled Trial Comparing Postoperative Pain Following TAH With GA vs. Combined GA + SAB","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2012-01","conditions":"Hysterectomy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Combination of Neostigmine and Glycopyrrolate","genericName":"Combination of Neostigmine and Glycopyrrolate","companyName":"James J. Peters Veterans Affairs Medical Center","companyId":"james-j-peters-veterans-affairs-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract parasympathomimetic side effects. Used for Reversal of neuromuscular blockade in anesthesia, Myasthenia gravis (neostigmine component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}